VOR | Vor Biopharma Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.8449 - 0.8817
52 Week Range	0.6300 - 3.14
Beta	-0.30
Implied Volatility	374.33%
IV Rank	43.20%
Day's Volume	230,918
Average Volume	580,953
Shares Outstanding	68,673,600
Market Cap	59,560,613
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.53
Forward P/E Ratio	N/A
EPS	-1.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	168
Country	USA
Website	VOR

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VOR's peers: ACET, CGEM, EWTX, HOWL, SNSE, GRCL, THRX, GLUE, DSGN, ERAS, TALS, NUVL, VTYX, ACLX, KNSA, BOLT, DAWN, LYRA, AUTL, FHTX, STTK, KYMR, NRIX, OABI

*Chart delayed

Analyzing fundamentals for VOR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see VOR Fundamentals page.

Watching at VOR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VOR Technicals page.